An antitumor cellular vaccine based on a mini-membrane IgE

Elisa A. Nigro, Elisa Soprana, Anna T. Brini, Alessandro Ambrosi, Vijay A. Yenagi, David Dombrowicz, Antonio G. Siccardi, Luca Vangelista

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The IgE-mediated immune system activation can be redirected to combat tumors. Mouse and human IgE have been shown to provide a potent adjuvant effect in antitumor vaccination, with a crucial role played by FcεRI. This effect results from T cell-mediated adaptive immune response. Modified vaccinia virus Ankara (MVA) has been used to infect IgE-loaded tumor cells. These results led to a shift toward a highly safe protocol employing membrane IgE (mIgE), thus eliminating any possible anaphylacto-genicity caused by circulating IgE. Evidence that human mIgE and a truncated version lacking IgE Fabs (tmIgE) bind and activate FcεRI has been fundamental and forms the core of this report. Human tmIgE has been engineered into a recombinant MVA (rMVA-tmIgE), and the expression of tmIgE and its transport to the surface of rMVA-tmIgE-infected cells has been detected by Western blot and cytofluorimetry, respectively. FcεRI activation by tmIgE has been confirmed by the release of β-hexosaminidase in a cell-to-cell contact assay using human FcεRI-transfected RBL-SX38 cells. The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcεRIα -/- human FcεRIa + mice, with results indicating a level of protection comparable to that obtained using soluble human IgE tumor cell loading. The rMVA-tmIgE vector represents a device that suits safe IgE-based antitumor vaccines, harboring the possibility to couple tmIgE with other gene insertions that might enhance the antitumor effect, thus bringing the field closer to the clinics.

Original languageEnglish
Pages (from-to)103-110
Number of pages8
JournalJournal of Immunology
Volume188
Issue number1
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

Immunoglobulin E
Vaccines
Membranes
Vaccinia virus
Vaccination
Hexosaminidases
Neoplasms
Insertional Mutagenesis
Adaptive Immunity
Immune System
Western Blotting
T-Lymphocytes
Equipment and Supplies

ASJC Scopus subject areas

  • Immunology

Cite this

Nigro, E. A., Soprana, E., Brini, A. T., Ambrosi, A., Yenagi, V. A., Dombrowicz, D., ... Vangelista, L. (2012). An antitumor cellular vaccine based on a mini-membrane IgE. Journal of Immunology, 188(1), 103-110. https://doi.org/10.4049/jimmunol.1101842

An antitumor cellular vaccine based on a mini-membrane IgE. / Nigro, Elisa A.; Soprana, Elisa; Brini, Anna T.; Ambrosi, Alessandro; Yenagi, Vijay A.; Dombrowicz, David; Siccardi, Antonio G.; Vangelista, Luca.

In: Journal of Immunology, Vol. 188, No. 1, 01.01.2012, p. 103-110.

Research output: Contribution to journalArticle

Nigro, EA, Soprana, E, Brini, AT, Ambrosi, A, Yenagi, VA, Dombrowicz, D, Siccardi, AG & Vangelista, L 2012, 'An antitumor cellular vaccine based on a mini-membrane IgE', Journal of Immunology, vol. 188, no. 1, pp. 103-110. https://doi.org/10.4049/jimmunol.1101842
Nigro EA, Soprana E, Brini AT, Ambrosi A, Yenagi VA, Dombrowicz D et al. An antitumor cellular vaccine based on a mini-membrane IgE. Journal of Immunology. 2012 Jan 1;188(1):103-110. https://doi.org/10.4049/jimmunol.1101842
Nigro, Elisa A. ; Soprana, Elisa ; Brini, Anna T. ; Ambrosi, Alessandro ; Yenagi, Vijay A. ; Dombrowicz, David ; Siccardi, Antonio G. ; Vangelista, Luca. / An antitumor cellular vaccine based on a mini-membrane IgE. In: Journal of Immunology. 2012 ; Vol. 188, No. 1. pp. 103-110.
@article{3c65f49232ef49608f2f7e3e30a78c9b,
title = "An antitumor cellular vaccine based on a mini-membrane IgE",
abstract = "The IgE-mediated immune system activation can be redirected to combat tumors. Mouse and human IgE have been shown to provide a potent adjuvant effect in antitumor vaccination, with a crucial role played by FcεRI. This effect results from T cell-mediated adaptive immune response. Modified vaccinia virus Ankara (MVA) has been used to infect IgE-loaded tumor cells. These results led to a shift toward a highly safe protocol employing membrane IgE (mIgE), thus eliminating any possible anaphylacto-genicity caused by circulating IgE. Evidence that human mIgE and a truncated version lacking IgE Fabs (tmIgE) bind and activate FcεRI has been fundamental and forms the core of this report. Human tmIgE has been engineered into a recombinant MVA (rMVA-tmIgE), and the expression of tmIgE and its transport to the surface of rMVA-tmIgE-infected cells has been detected by Western blot and cytofluorimetry, respectively. FcεRI activation by tmIgE has been confirmed by the release of β-hexosaminidase in a cell-to-cell contact assay using human FcεRI-transfected RBL-SX38 cells. The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcεRIα -/- human FcεRIa + mice, with results indicating a level of protection comparable to that obtained using soluble human IgE tumor cell loading. The rMVA-tmIgE vector represents a device that suits safe IgE-based antitumor vaccines, harboring the possibility to couple tmIgE with other gene insertions that might enhance the antitumor effect, thus bringing the field closer to the clinics.",
author = "Nigro, {Elisa A.} and Elisa Soprana and Brini, {Anna T.} and Alessandro Ambrosi and Yenagi, {Vijay A.} and David Dombrowicz and Siccardi, {Antonio G.} and Luca Vangelista",
year = "2012",
month = "1",
day = "1",
doi = "10.4049/jimmunol.1101842",
language = "English",
volume = "188",
pages = "103--110",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - An antitumor cellular vaccine based on a mini-membrane IgE

AU - Nigro, Elisa A.

AU - Soprana, Elisa

AU - Brini, Anna T.

AU - Ambrosi, Alessandro

AU - Yenagi, Vijay A.

AU - Dombrowicz, David

AU - Siccardi, Antonio G.

AU - Vangelista, Luca

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The IgE-mediated immune system activation can be redirected to combat tumors. Mouse and human IgE have been shown to provide a potent adjuvant effect in antitumor vaccination, with a crucial role played by FcεRI. This effect results from T cell-mediated adaptive immune response. Modified vaccinia virus Ankara (MVA) has been used to infect IgE-loaded tumor cells. These results led to a shift toward a highly safe protocol employing membrane IgE (mIgE), thus eliminating any possible anaphylacto-genicity caused by circulating IgE. Evidence that human mIgE and a truncated version lacking IgE Fabs (tmIgE) bind and activate FcεRI has been fundamental and forms the core of this report. Human tmIgE has been engineered into a recombinant MVA (rMVA-tmIgE), and the expression of tmIgE and its transport to the surface of rMVA-tmIgE-infected cells has been detected by Western blot and cytofluorimetry, respectively. FcεRI activation by tmIgE has been confirmed by the release of β-hexosaminidase in a cell-to-cell contact assay using human FcεRI-transfected RBL-SX38 cells. The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcεRIα -/- human FcεRIa + mice, with results indicating a level of protection comparable to that obtained using soluble human IgE tumor cell loading. The rMVA-tmIgE vector represents a device that suits safe IgE-based antitumor vaccines, harboring the possibility to couple tmIgE with other gene insertions that might enhance the antitumor effect, thus bringing the field closer to the clinics.

AB - The IgE-mediated immune system activation can be redirected to combat tumors. Mouse and human IgE have been shown to provide a potent adjuvant effect in antitumor vaccination, with a crucial role played by FcεRI. This effect results from T cell-mediated adaptive immune response. Modified vaccinia virus Ankara (MVA) has been used to infect IgE-loaded tumor cells. These results led to a shift toward a highly safe protocol employing membrane IgE (mIgE), thus eliminating any possible anaphylacto-genicity caused by circulating IgE. Evidence that human mIgE and a truncated version lacking IgE Fabs (tmIgE) bind and activate FcεRI has been fundamental and forms the core of this report. Human tmIgE has been engineered into a recombinant MVA (rMVA-tmIgE), and the expression of tmIgE and its transport to the surface of rMVA-tmIgE-infected cells has been detected by Western blot and cytofluorimetry, respectively. FcεRI activation by tmIgE has been confirmed by the release of β-hexosaminidase in a cell-to-cell contact assay using human FcεRI-transfected RBL-SX38 cells. The rMVA-tmIgE antitumor vaccination strategy has been investigated in FcεRIα -/- human FcεRIa + mice, with results indicating a level of protection comparable to that obtained using soluble human IgE tumor cell loading. The rMVA-tmIgE vector represents a device that suits safe IgE-based antitumor vaccines, harboring the possibility to couple tmIgE with other gene insertions that might enhance the antitumor effect, thus bringing the field closer to the clinics.

UR - http://www.scopus.com/inward/record.url?scp=84855406139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855406139&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1101842

DO - 10.4049/jimmunol.1101842

M3 - Article

C2 - 22124126

AN - SCOPUS:84855406139

VL - 188

SP - 103

EP - 110

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -